Loading
A phase 2 trial of FID007 in head and neck squamous cell carcinoma, run by Fulgent Pharma LLC., active and no longer recruiting.
FID-007 and Cetuximab in Treating Patients With Advanced Head and Neck Squamous Cell Carcinoma is a phase 2 interventional study registered as NCT06332092 by Fulgent Pharma LLC., with 46 participants enrolled, started 2024-04-10 and due to reach its primary completion in 2025-12-31. Interventions recorded: FID007.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Head and neck squamous cell carcinoma and the tag pipeline.
Shares Cetuximab, Monoclonal antibodies and the tag pipeline.
Shares Head and neck squamous cell carcinoma and the tag pipeline.
Shares Cetuximab, Head and neck squamous cell carcinoma and the tag pipeline.
Shares Cetuximab, Monoclonal antibodies and the tag pipeline.
Shares Head and neck squamous cell carcinoma and the tag pipeline.
Shares Cetuximab, Head and neck squamous cell carcinoma and the tag pipeline.
Shares Cetuximab, Monoclonal antibodies, Head and neck squamous cell carcinoma.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/